Dr. Satya (Nanu) Das is a medical oncologist with a background in gastrointestinal (GI) cancer, neuroendocrine cancer and Phase 1 trials. Before joining industry, Nanu was an Assistant Professor of Medicine at Vanderbilt University Medical Center, where he led the Neuroendocrine Tumor (NET) program and co-led the Upper-GI Malignancies program. He was the recipient of multiple national career development awards, including the Paul Calabresi K12 Award and NET Research Foundation Investigator Award. He also served on multiple national guideline panels, including the NCCN Guidelines for NET and ASCO Expert Panel for Gastroenteropancreatic NETs, and national drug development workshop panels, including the NCI Clinical Trials Planning Meeting for Radioligand Therapy and the NCI NET Task Force. After transitioning to industry, Nanu served as a global medical director at AstraZeneca, working on the development of trastuzumab deruxtecan for multiple first line GI cancer indications. He then transitioned to a Senior Medical Director role at Cullgen Inc, where he led clinical development, prior to joining Phanes.

Nanu holds an MD from Emory University School of Medicine and a Masters of Clinical Investigation (MSCI) from Vanderbilt University. He has more than 60 peer reviewed publications and continues to review for journals including JAMA Oncology and Clinical Cancer Research.